secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0000950170-23-028265
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Galecto stockholders elect three Class III directors and ratify EY as auditor at 2023 annual meeting
--------------------------------------------------------------------------------

- Elected Jayson Dallas, Amit Munshi, and Hans Schambye as Class III directors with 9.9M, 10.5M, and 10.5M votes for, respectively.
- Ratified EY Godkendt Revisionspartnerselskab as independent auditor for FY 2023 with 16.0M votes for, 52,661 against.
- Broker non-votes of 5.5M on director election; no broker non-votes on auditor ratification.
- Total shares present or represented: 16.1M out of 25.7M entitled to vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000095017023028265/0000950170-23-028265-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000095017023028265/glto-20230614.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-028265

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer